Decitabine

The need for new treatment regimens in older AML patients

The need for new treatment regimens in older AML patients

The search for better post-MPN AML treatment: decitabine and ruxolitinib

The search for better post-MPN AML treatment: decitabine and ruxolitinib

Targeting BCL-2 in MDS

Targeting BCL-2 in MDS

Therapy strategies for accelerated and blastic phase MPN

Therapy strategies for accelerated and blastic phase MPN

Srdan Verstovsek

Harnessing apoptosis in AML

Harnessing apoptosis in AML

Marina Konopleva

Targeting p53 in MDS

Targeting p53 in MDS

MBG453 with hypomethylating agents in AML and high-risk MDS

MBG453 with hypomethylating agents in AML and high-risk MDS

Combining hypomethylating agents in AML

Combining hypomethylating agents in AML

Significance of oral hypomethylating agents

Significance of oral hypomethylating agents

hypomethylating agents in AML

hypomethylating agents in AML

Azacitidine and decitabine in treatment naive AML patients

Azacitidine and decitabine in treatment naive AML patients

Immune checkpoint inhibitors in MDS and AML

Immune checkpoint inhibitors in MDS and AML

$Onvansertib and decitabine in relapsed/refractory AML$ 2:41

Onvansertib and decitabine in relapsed/refractory AML

Novel epigenetic drugs and their use in myeloid malignancies

Novel epigenetic drugs and their use in myeloid malignancies

Anti-TIM-3 antibody MBG453 + hypomethylating agents for high-risk MDS & AML

Anti-TIM-3 antibody MBG453 + hypomethylating agents for high-risk MDS & AML

Rationale for 10-day decitabine with venetoclax for high-risk AML

Rationale for 10-day decitabine with venetoclax for high-risk AML

1
2
3
4
5
Next